Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 15.97% and Operating profit at 24.64% over the last 5 years
2
Flat results in Mar 26
3
With ROE of 13.58%, it has a expensive valuation with a 4.67 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 10,217 Million (Mid Cap)
37.00
NA
0.39%
-0.31
13.58%
5.16
Revenue and Profits:
Net Sales:
395 Million
(Quarterly Results - Jun 2026)
Net Profit:
62 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
16.24%
0%
16.24%
6 Months
-12.7%
0%
-12.7%
1 Year
-40.28%
0%
-40.28%
2 Years
25.92%
0%
25.92%
3 Years
23.38%
0%
23.38%
4 Years
159.78%
0%
159.78%
5 Years
222.05%
0%
222.05%
Inner Mongolia Furui Medical Science Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
15.97%
EBIT Growth (5y)
24.64%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.39
Sales to Capital Employed (avg)
0.77
Tax Ratio
25.12%
Dividend Payout Ratio
25.61%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
24.52%
ROE (avg)
9.89%
Valuation key factors
Factor
Value
P/E Ratio
37
Industry P/E
Price to Book Value
4.96
EV to EBIT
23.41
EV to EBITDA
19.49
EV to Capital Employed
6.77
EV to Sales
5.67
PEG Ratio
0.65
Dividend Yield
NA
ROCE (Latest)
28.92%
ROE (Latest)
13.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
394.60
383.00
3.03%
Operating Profit (PBDIT) excl Other Income
113.60
100.20
13.37%
Interest
1.30
0.80
62.50%
Exceptional Items
2.20
0.00
Consolidate Net Profit
62.40
36.30
71.90%
Operating Profit Margin (Excl OI)
212.60%
194.80%
1.78%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 3.03% vs 19.76% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 71.90% vs -21.77% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,592.80
1,346.30
18.31%
Operating Profit (PBDIT) excl Other Income
504.50
379.90
32.80%
Interest
3.60
3.00
20.00%
Exceptional Items
-13.10
-7.70
-70.13%
Consolidate Net Profit
258.40
195.90
31.90%
Operating Profit Margin (Excl OI)
250.90%
211.50%
3.94%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 18.31% vs 17.77% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 31.90% vs 10.62% in Dec 2024
About Inner Mongolia Furui Medical Science Co., Ltd. 
Inner Mongolia Furui Medical Science Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






